David Hirsch, MD, PhD
Dr. Hirsch is a Managing Director and Founder of Longitude Capital. Prior to Longitude Capital, Dr. Hirsch was a Vice President of Pequot Ventures, where he worked in the life sciences practice. Prior to Pequot Ventures, Dr. Hirsch was an Engagement Manager in the pharmaceutical practice of McKinsey & Company. Dr. Hirsch currently serves on the boards of Alpha-9 Theranostics, Molecular Templates (MTEM), Rapid Micro Biosystems (RPID), and Tricida (TCDA). Selected prior board memberships include Amunix Pharmaceuticals, Civitas Therapeutics (acquired by Acorda), Collegium Pharmaceutical (COLL), Inflazome (acquired by Roche), Poseida Therapeutics (PSTX), Precision Therapeutics, Velicept Therapeutics, and Zavante Therapeutics (acquired by Nabriva (NBVA)). Dr. Hirsch also led Longitude Capital’s investments in Amarin (AMRN) and Cadence Pharmaceuticals (CADX, acquired by Mallinckrodt). Dr. Hirsch holds a PhD in Biology from the Massachusetts Institute of Technology, an MD from Harvard Medical School, and a BA in Biology from The Johns Hopkins University.